Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30355137.
- Also identified by DOI 10.1161/CIRCRESAHA.118.311134.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hydrogen sulfide (H<sub>2</sub>S)-a potent gaseous signaling molecule-has emerged as a critical regulator of cardiovascular homeostasis. H<sub>2</sub>S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H<sub>2</sub>S-donating agents and the genetic manipulation of H<sub>2</sub>S-producing enzymes have revealed multiple beneficial effects of H<sub>2</sub>S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H<sub>2</sub>S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H<sub>2</sub>S-mediated signaling pathways. This review will discuss recently developed H<sub>2</sub>S therapeutics, introduce signaling pathways that are influenced by H<sub>2</sub>S-dependent sulfhydration, and explore the dual-protective effect of H<sub>2</sub>S in cardiorenal syndrome.
Medical subject headings
- Cardiovascular Diseases
- Hydrogen Sulfide